Table 1

Summary of results with 95% bias-corrected bootstrap confidence intervals

With supposed higher background incidence due to increased hormone therapy use (+21%)

Combined estimate (50 to 69 years) with non-adjusted background incidence

Women aged 50 to 59 years

Women aged 60 to 69 years

Combined estimate (50 to 69 years)

Time taken from 10 mm to 20 mm (years)

Mean

1.4 (1.1, 1.5)

2.1 (1.8, 2.4)

1.7 (1.5, 1.8)

2.0 (1.8, 2.2)

Standard deviation

1.9 (1.7, 2.2)

2.4 (2.1, 2.7)

2.2 (2.0, 2.4)

2.7 (2.5, 2.9)

Volume doubling time at 15 mm (days)

25th percentile

29 (19, 36)

65 (47, 79)

41 (32, 48)

29 (21, 35)

50th percentile

73 (56, 86)

143 (116, 165)

99 (84, 111)

94 (77, 107)

75th percentile

180 (148, 205)

308 (253, 352)

234 (204, 259)

287 (243, 322)

Screening test sensitivity

5 mm

29 (21, 36)

24 (18, 30)

26 (22, 31)

26 (22, 31)

10 mm

92 (88, 99)

91 (86, 98)

91 (88, 96)

91 (87, 96)

Indicators of potential screening efficacy

Mean sojourn time (years)

2.3 (2.0, 2.6)

3.5 (3.1, 3.9)

2.8 (2.6, 3.1)

3.4 (3.1, 3.6)

Proportion of tumors visible on screening

0.95 (0.94, 0.96)

0.95 (0.95, 0.96)

0.95 (0.95, 0.96)

0.95 (0.95, 0.96)

Weedon-Fekjær et al. Breast Cancer Research 2008 10:R41   doi:10.1186/bcr2092